Pacira BioSciences, Inc. — Form 8-K Summary
Reporting date: October 8, 2026. This filing reports a merger agreement with Viatris Inc.; it does not report a financial-results period.
Transaction and key terms
- Viatris, through its wholly owned subsidiary Peach Purchaser Sub, agreed to acquire Pacira in a cash tender offer at $36.50 per share, without interest and subject to applicable withholding taxes.
- The tender offer is expected to commence as promptly as practicable, and no later than 15 business days after signing. It has not yet commenced as of this filing.
- The offer is conditioned, among other things, on tenders representing at least one share more than 50% of Pacira’s outstanding shares, together with shares owned by the buyer and its affiliates, and expiration or termination of the applicable HSR waiting period and any relevant timing agreement.
- After the offer, and subject to the agreement’s conditions, the buyer will merge into Pacira under DGCL Section 251(h). Pacira will survive as a wholly owned Viatris subsidiary; no Pacira stockholder vote is required for the merger.
- At the merger’s effective time, eligible outstanding shares will convert into the right to receive the offer price. Shares held by Pacira, Viatris or their specified subsidiaries, and shares subject to properly perfected appraisal rights, are excluded.
- Outstanding options, PSUs, RSUs and certain cash-based awards will be canceled and converted into cash under the agreement’s specified formulas and award terms. Options with an exercise price at or above $36.50 receive no consideration.
Financial terms and other metrics
The filing provides no revenue, profit, cash flow, margin, debt, liquidity or operating-performance figures, and no standalone financial outlook. The stated transaction consideration is $36.50 per share. Pacira may owe Viatris a $62.0 million termination fee in specified circumstances, including certain terminations to accept a superior offer.
Material changes, outlook and contingencies
- Pacira’s board unanimously approved the merger agreement and recommended that stockholders tender their shares.
- Until the buyer accepts tendered shares or the agreement terminates, Pacira is generally required to operate in the ordinary course, subject to exceptions. The agreement restricts solicitation of competing proposals, with specified fiduciary and superior-offer exceptions.
- Completion is not assured. Risks include failure to meet the tender threshold, delay or failure to obtain regulatory clearance, competing proposals, and other closing conditions not being satisfied or waived.
- The filing identifies broader risks including integration and synergy execution, business and product performance, regulatory and legal matters, manufacturing and supply continuity, personnel retention, competition, intellectual property, customer and supplier relationships, and economic conditions.
- The tender-offer materials and Pacira’s Schedule 14D-9 are to be filed with the SEC when available. The filing advises stockholders to review them before making a decision.
Investor facts to verify
- Review the offer documents and Schedule 14D-9 for final terms, conditions, deadlines and the board’s recommendation details.
- Track tender participation, HSR review and any other regulatory or timing requirements.
- Check subsequent SEC filings for amendments, competing proposals, termination-fee exposure or changes to the expected transaction timetable.
- Review the merger agreement and relevant award documents for treatment of individual equity and cash-based awards.